News

Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021
12/04/2021
Ascletis’ Strategic Partner Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH
23/03/2021
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH
09/03/2021
Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH
25/02/2021
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41
21/02/2021
Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41
12/01/2021